Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Efficacy outcomes in patients using alefacept in the AWARE study.

Landells I, Searles G, Bissonnette R, Shear NH, Vender R, Lui H.

J Cutan Med Surg. 2009 Dec;13 Suppl 3:S122-30.

PMID:
20053324
2.

The AWARE study: methodology and baseline characteristics.

Bissonnette R, Searles G, Landells I, Shear NH, Papp K, Lui H, Gulliver WP, Lynde C.

J Cutan Med Surg. 2009 Dec;13 Suppl 3:S113-21.

PMID:
20053323
3.

Update on alefacept safety.

Wexler D, Searles G, Landells I, Shear NH, Bissonnette R, Papp K, Poulin Y, Langley R, Gulliver WP.

J Cutan Med Surg. 2009 Dec;13 Suppl 3:S139-47.

PMID:
20053326
4.

Patterns of combination therapy with alefacept for the treatment of psoriasis in Canada in the AWARE study.

Searles G, Bissonnette R, Landells I, Shear NH, Papp K, Lui H.

J Cutan Med Surg. 2009 Dec;13 Suppl 3:S131-8.

PMID:
20053325
5.

An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis.

Ortonne JP, Khemis A, Koo JY, Choi J.

J Eur Acad Dermatol Venereol. 2005 Sep;19(5):556-63.

PMID:
16164708
6.
7.

The next phase of real-world clinical experience with alefacept: the AWARE-2 registry.

Searles G, Bissonnette R, Landells I, Shear NH.

J Cutan Med Surg. 2009 Dec;13 Suppl 3:S148-52. No abstract available.

PMID:
20053327
9.

A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.

Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN; Alefacept Clinical Study Group.

J Am Acad Dermatol. 2002 Dec;47(6):821-33.

PMID:
12451365
11.

The safety profile and sustained remission associated with response to multiple courses of intramuscular alefacept for treatment of chronic plaque psoriasis.

Roberts JL, Ortonne JP, Tan JK, Jaracz E, Frankel E; Alefacept Clinical Study Group.

J Am Acad Dermatol. 2010 Jun;62(6):968-78. doi: 10.1016/j.jaad.2009.07.032. Epub 2010 Apr 14.

PMID:
20392521
12.

A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis.

Krueger GG, Gottlieb AB, Sterry W, Korman N, Van De Kerkhof P.

J Dermatolog Treat. 2008;19(3):146-55. doi: 10.1080/09546630701846103.

PMID:
18569270
13.
15.

Intralesional injections of alefacept may predict systemic response to intramuscular alefacept: results from a pilot study.

Bhutani T, Kamangar F, Zitelli K, Chiang C, Gattu S, Nguyen T, Becker E, Koo J.

J Dermatolog Treat. 2013 Oct;24(5):348-50. doi: 10.3109/09546634.2012.672712. Epub 2012 Jun 5.

PMID:
22506829
16.

Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis.

Legat FJ, Hofer A, Wackernagel A, Salmhofer W, Quehenberger F, Kerl H, Wolf P.

Arch Dermatol. 2007 Aug;143(8):1016-22.

PMID:
17709660
17.

Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study.

Huang PH, Liao YH, Wei CC, Tseng YH, Ho JC, Tsai TF.

J Eur Acad Dermatol Venereol. 2008 Aug;22(8):923-30. doi: 10.1111/j.1468-3083.2007.02575.x. Epub 2008 Feb 27.

PMID:
18312328
18.

An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis.

Gribetz CH, Blum R, Brady C, Cohen S, Lebwohl M.

J Am Acad Dermatol. 2005 Jul;53(1):73-5.

PMID:
15965424
19.

A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response.

Lui H, Gulliver W, Tan J, Hong CH, Hull P, Shear NH, Paradiso-Hardy F, Bissonette R.

J Drugs Dermatol. 2012 Aug;11(8):929-37.

PMID:
22859237
20.

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE; Alefacept Clinical Study Group.

Arch Dermatol. 2003 Jun;139(6):719-27.

PMID:
12810502

Supplemental Content

Support Center